The Food and Drug Administration (FDA) has approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in
An electric bandage. Courtesy of Ohio State University Wexner Medical Center
Researchers from Liverpool School of Tropical Medicine (LSTM) Cochrane Infectious Diseases Group publish two systematic reviews this week about the safety of mefloquine (Lariam) for preventing malaria in travelers.
The deadliest malaria parasite needs two proteins to infect red blood cells. Courtesy of NIH
Researchers have shown that genetic diversity plays a key role in enabling drug resistance to evolve.
A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new regulator of the innate immune response--the immediate, natural immune response to foreign invaders. The study, published recently in Nature Microbiology, suggests that therapeutics that modulate the regulator--an immune checkpoint--may represent the next generation of antiviral drugs, vaccine adjuvants, cancer immunotherapies, and treatments for autoimmune disease.